XML 37 R6.htm IDEA: XBRL DOCUMENT v3.26.1
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY - EUR (€)
€ in Thousands
Total
Heights convertible notes
Kreos OCABSA
Kreos A & B BSA
Kreos & Claret financing
Other equity agreement
SHARE CAPITAL
SHARE CAPITAL
Heights convertible notes
SHARE CAPITAL
Kreos OCABSA
SHARE CAPITAL
Kreos A & B BSA
SHARE CAPITAL
Other equity agreement
PREMIUMS RELATED TO SHARE CAPITAL
PREMIUMS RELATED TO SHARE CAPITAL
Heights convertible notes
PREMIUMS RELATED TO SHARE CAPITAL
Kreos OCABSA
PREMIUMS RELATED TO SHARE CAPITAL
Kreos A & B BSA
PREMIUMS RELATED TO SHARE CAPITAL
Kreos & Claret financing
PREMIUMS RELATED TO SHARE CAPITAL
Other equity agreement
TRANSLATION RESERVE
RETAINED EARNINGS
RETAINED EARNINGS
Kreos OCABSA
NET LOSS FOR THE YEAR
Number of shares issued at beginning of period (in shares) at Dec. 31, 2022 22,313,185                                        
Reconciliation of number of shares outstanding [abstract]                                          
Capital increase from issuance of ordinary shares (in shares) 40,325,500                                        
Exercises of share warrants (in shares)       99,583   190,550                              
Number of shares issued at end of period (in shares) at Dec. 31, 2023 62,928,818                                        
Equity at beginning of period at Dec. 31, 2022 € 7,189           € 223         € 150,476           € 0 € (82,770)   € (60,740)
Changes in equity [abstract]                                          
Net loss for the period (147,740)                                       (147,740)
Other comprehensive income (loss) 225                                 112 112    
Total comprehensive income (loss) for the period (147,516)                                 112 112   (147,740)
Appropriation of prior period net loss 0                                   (60,740)   60,740
Capital increase from issuance of ordinary shares 353,377           403         352,974                  
Transaction costs related to capital increase (28,111)                     (28,111)                  
Issue of convertible notes 1,030                     1,030                  
Exercises of shares warrants       € 1,850   € 2       € 1 € 2       € 1,849            
Shares based compensation expense 8,179                                   8,179    
Transactions on treasury shares 10                                   10    
Equity at end of period at Dec. 31, 2023 € 196,010           629         478,218           112 (135,210)   (147,740)
Reconciliation of number of shares outstanding [abstract]                                          
Exercises of share warrants (in shares) 4,000         4,000                              
Issue of free shares (in shares) 415,019                                        
Number of shares issued at end of period (in shares) at Dec. 31, 2024 63,347,837                                        
Changes in equity [abstract]                                          
Net loss for the period € (176,242)                                       (176,242)
Other comprehensive income (loss) (219)                                 (187) (31)    
Total comprehensive income (loss) for the period (176,461)                                 (187) (31)   (176,242)
Appropriation of prior period net loss 0                                   (147,740)   147,740
Transaction costs related to capital increase 446                     446                  
Issue of share warrants 200                     200                  
Exercises of shares warrants 45                     45                  
Issue of free shares 1           4         (4)                  
Shares based compensation expense 20,224                                   20,224    
Transactions on treasury shares 120                                   120    
Equity at end of period at Dec. 31, 2024 € 40,584           633         478,905           (75) (262,638)   (176,242)
Reconciliation of number of shares outstanding [abstract]                                          
Capital increase from issuance of ordinary shares (in shares) 11,679,400                                        
Exercises of share warrants (in shares)         525,913 257,087                              
Conversion of convertible instruments (in shares)   920,377 1,178,084                                    
Issue of free shares (in shares) 627,714                                        
Number of shares issued at end of period (in shares) at Dec. 31, 2025 78,536,412                                        
Changes in equity [abstract]                                          
Net loss for the period € (336,102)                                       (336,102)
Other comprehensive income (loss) 2,477                                 2,384 93    
Total comprehensive income (loss) for the period (333,625)                                 2,384 93   (336,102)
Appropriation of prior period net loss 0                                   (176,242)   176,242
Capital increase from issuance of ordinary shares 637,462           117         637,345                  
Transaction costs related to capital increase (40,306)                     (40,306)                  
Issue of share warrants 300                     300                  
Exercises of shares warrants         € 33,768 € 3,346 5       € 3         € 33,763 € 3,343        
Conversion of Kreos Claret OCABSA and Heights notes   € 53,921 € 24,359         € 9 € 12       € 53,912 € 23,338           € 1,009  
Issue of free shares 0           6         (6)                  
Shares based compensation expense 35,397                                   35,397    
Equity at end of period at Dec. 31, 2025 € 455,205           € 785         € 1,190,593           € 2,309 € (402,380)   € (336,102)